Serous Cystadenoma

A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)

Also Known As:

Networked: 244 relevant articles (3 outcomes, 10 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Mucinous Cystadenoma
2.	Cysts
3.	Pancreatitis
4.	Pathologic Constriction (Stenosis)
5.	Neoplasms (Cancer)

Experts

1.	Klimstra, David S: 5 articles (10/2012 - 02/2006)
2.	Brustmann, Hermann: 5 articles (07/2008 - 01/2002)
3.	Palazzo, Laurent: 4 articles (11/2020 - 06/2004)
4.	Hruban, Ralph H: 4 articles (01/2017 - 12/2011)
5.	Dal Molin, Marco: 3 articles (01/2017 - 12/2011)
6.	Wolfgang, Christopher L: 3 articles (01/2017 - 12/2011)
7.	Conwell, Darwin L: 3 articles (11/2016 - 01/2014)
8.	Andruss, Bernard F: 3 articles (11/2014 - 09/2012)
9.	Szafranska-Schwarzbach, Anna E: 3 articles (11/2014 - 09/2012)
10.	Braga, Letícia da Conceição: 3 articles (05/2014 - 08/2012)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Serous Cystadenoma:

1.	Fluorescein (Funduscein)FDA LinkGeneric 11/01/2020 - "Thirteen (81 %) nCLE-CS reached consensus addressing indications (non-communication PCL meeting criteria for EUS-FNA or with prior non-diagnostic EUS-FNA), diagnostic outcomes (improved accuracy for mucinous PCLs and serous cystadenomas with substantial interobserver agreement of image patterns), low incidence of adverse events (fluorescein-associated and pancreatitis), procedural processes (nCLE duration, manipulation of needle with probe), and training (physician knowledge and competence). "
2.	Proteins (Proteins, Gene)FDA Link 02/01/2011 - "PDCD5 was expressed in all normal ovaries and serous cystadenomas, 80% (16/20) of normal ovarian tissues and 76.9% (20/26) of serous cystadenomas with moderate or strong PDCD5 protein expression. " 11/01/2016 - "Based on this, we developed a panel for targeted proteomic analysis using the multiple reaction monitoring (MRM) method for validation of 51 proteins in individual samples of high-grade serous ovarian tumor fluids (malignant) and benign serous cystadenoma tumor fluids. " 10/29/2013 - "Protein levels of hOGG1 were remarkably decreased in HG-SOC (p < 0.01), but not in LG-SOC and serous cystadenoma compared with the tissue adjacent to carcinoma. " 01/01/2010 - "NASP and RCAS1 proteins were more frequently expressed in ovarian cancer tissues than with normal ovarian tissue and serous cystadenomas and MRE11 was less frequently expressed. " 02/01/2009 - "The expression of THY1 protein was significantly down-regulated in ovarian serous cystadenocarcinoma tissues compared with that in normal ovarian tissues and ovarian serous cystadenoma tissues (P < 0.05). "
3.	ParaffinIBA 11/28/2014 - "Sixty-eight surgically resected formalin fixed, paraffin embedded pancreatic specimens were analyzed, including: 1) benign (20 serous cystadenoma (SCA)), 2) pre-malignant (10 mucinous cystic neoplasm (MCN), 10 branch duct intraductal papillary mucinous neoplasm (BD-IPMN), 9 main duct IPMN (MD-IPMN)), 3) malignant (19 PDAC). " 02/01/2009 - "Immunohistochemistry was performed to detect the expression of THY1 gene in formalin-fixed, paraffin-embedded specimens of normal ovaries (n = 25), ovarian serous cystadenoma (n = 25), and serous cystadenocarcinoma (n = 53). " 07/01/2012 - "Multiple tissue microarrays (TMA) were created from cores of formalin-fixed paraffin-embedded blocks containing pancreatic adenocarcinomas (n=112), neuroendocrine tumors (n=99), serous cystadenomas (n=28), and SPT (n=14) as well as normal pancreas (n=12). " 01/01/1992 - "Flow cytometric analysis of DNA content and ras p21 expression were studied in paraffin-embedded normal ovary (NO, n = 10), serous cystadenoma (SA, n = 11), serous tumors of low malignant potential (LMP, n = 13), and papillary serous cystadenocarcinoma (SCa, n = 7). " 01/01/1996 - "To establish a basis for the interpretation of DNA flow cytometric results of gynecologic neoplasms, paraffin blocks from 121 patients with a diagnosis of serous cystadenoma (n = 37), mucinous cystadenoma (n = 28), leiomyoma (n = 41), and fibrothecoma (n = 15), and normal tissue samples obtained from some of these patients, including ovary (n = 20), cervix (n = 20), and myometrium (n = 20) were analyzed for nuclear DNA content. "
4.	Formaldehyde (Formol)FDA Link 11/28/2014 - "Sixty-eight surgically resected formalin fixed, paraffin embedded pancreatic specimens were analyzed, including: 1) benign (20 serous cystadenoma (SCA)), 2) pre-malignant (10 mucinous cystic neoplasm (MCN), 10 branch duct intraductal papillary mucinous neoplasm (BD-IPMN), 9 main duct IPMN (MD-IPMN)), 3) malignant (19 PDAC). " 02/01/2009 - "Immunohistochemistry was performed to detect the expression of THY1 gene in formalin-fixed, paraffin-embedded specimens of normal ovaries (n = 25), ovarian serous cystadenoma (n = 25), and serous cystadenocarcinoma (n = 53). " 07/01/2012 - "Multiple tissue microarrays (TMA) were created from cores of formalin-fixed paraffin-embedded blocks containing pancreatic adenocarcinomas (n=112), neuroendocrine tumors (n=99), serous cystadenomas (n=28), and SPT (n=14) as well as normal pancreas (n=12). " 04/01/2009 - "The study was performed on formalin-fixed, paraffin-embedded tissue samples from 75 epithelial ovarian tumors, 15 serous cystadenomas, 15 mucinous cystadenomas, 5 borderline serous cystadenomas, 5 borderline mucinous cystadenomas, 15 serous cystadenocarcinomas, 15 mucinous cystadenocarcinomas and 5 endometrioid carcinomas. " 09/01/2005 - "Formalin-fixed, paraffin-embedded archival tissue sections of 10 benign serous cystadenomas, 10 serous neoplasms of low malignant potential (LMP), and 41 serous ovarian carcinomas were immunostained with antibodies to hTERT and c-kit. "
5.	Tumor Biomarkers (Tumor Markers)IBA 03/01/2000 - "Two patients with serous cystadenoma had high levels of tumor markers (false-positive). " 05/01/1995 - "The tumor marker NB/70K was measured in aspirated cyst fluid from 13 inflammatory pseudocysts and 11 serous cystadenomas by a commercial immunoassay. " 06/01/2004 - "The aim of this study was to determine the EUS and tumor marker characteristics of mucinous cystadenoma compared with macrocystic serous cystadenomas. " 01/01/1994 - "The concentration of the tumor marker CA 15-3 was measured by immunoassay in cyst fluid from six pseudocysts, five serous cystadenomas, three mucinous cystic neoplasms, and six mucinous cystadenocarcinomas. " 02/15/1982 - "it was concluded that primitive cells in inclusion cysts elaborate the same tumor markers found in serous cystadenoma and cystadenocarcinoma of the ovary. "
6.	Messenger RNA (mRNA)IBA 03/05/2013 - "And the mRNA expressions of GRP78 in normal ovarian tissue, ovarian serous cystadenoma and ovarian serous cystadenocarcinoma were 0.134 ± 0.021, 0.121 ± 0.032 and 0.685 ± 0.085 respectively. " 05/01/2017 - "RT-PCR, westem blot, MTT and immunohistochemistry were used to detect the expression levels of PDCD1 mRNA and protein in human ovarian cancer cell lines (SKOV3, 3AO, CAOV3 and OVCAR3), human normal ovary, serous cystadenoma, and serous cystadenocarcinoma tissue. " 02/01/2004 - "Epithelial telomerase reverse transcriptase mRNA expression was detected in 28 of 31 epithelial ovarian carcinomas, 1 of 1 malignant granulosa cell tumor, 7 of 9 serous borderline ovarian tumors, 11 of 11 mucinous borderline ovarian tumors, 4 of 5 serous cystadenofibromas, 2 of 4 serous cystadenomas, 8 of 8 mucinous cystadenomas, and 0 of 6 normal ovaries except the corpus luteum. " 07/01/1997 - "The present study analyzes and compares the expression of its precursor beta 1-latency-associated peptide (beta 1-LAP), its latent binding protein (LTBP), and its mRNA in ductal adenocarcinoma (n = 10), in IPMN (n = 8), in serous cystadenoma (n = 2), and in normal tissues (n = 5). " 05/01/1996 - "In situ hybridization gave negative results for glycodelin mRNA in normal ovary, whereas in ovarian tumors strong expression of both the glycodelin mRNA and the protein were found in benign and malignant serous cystadenomas, mucinous ovarian tumors being negative. "
7.	Glycoproteins (Glycoprotein)IBA 01/01/2017 - "In this study, we presented an integrated proteomics and glycoproteomics approach to identify changes of glycoproteins in protein expression and glycosylation occupancy in HGSC and serous cystadenoma and determined the changes of glycosylation occupancy that are associated with malignant and benign tumor tissues. " 01/01/2017 - "In this study, we used an integrated proteomics and glycoproteomics approach to analyze global glycoprotein abundance and glycosylation occupancy for proteins from high-grade ovarian serous carcinoma (HGSC) and serous cystadenoma, a benign epithelial ovarian tumor, by using LC-MS/MS-based technique. " 03/01/1988 - "Sections of normal ovarian surface epithelium, benign serous cystadenomas, borderline serous cystadenomas and serous cyst-adenocarcinomas were stained with a pattern of lectins (Con A, WGA, SBA, DBA, UEA I, PNA and RCA I) to determine the different glycoproteins and their cellular changes. "
8.	Chemokine CCL5IBA 01/01/2011 - "This study was undertaken to evaluate RANTES levels in the peritoneal fluid (PF) and plasma of patients with ovarian cancer (n=73), serous cystadenoma (n=32) or normal controls (n=9). "
9.	Peptides (Polypeptides)IBA 07/01/1997 - "The present study analyzes and compares the expression of its precursor beta 1-latency-associated peptide (beta 1-LAP), its latent binding protein (LTBP), and its mRNA in ductal adenocarcinoma (n = 10), in IPMN (n = 8), in serous cystadenoma (n = 2), and in normal tissues (n = 5). "
10.	Nitric Oxide (Nitrogen Monoxide)FDA Link 12/01/2000 - "The present study evaluated the concentrations of inhibin A and inhibin B and the relationship with oestradiol and nitric oxide metabolites in fluid collected from benign ovarian serous cystadenomas (n = 15). " 12/01/2000 - "High concentrations of inhibin A and inhibin B in ovarian serous cystadenoma: relationship with oestradiol and nitric oxide metabolites."

Therapies and Procedures

1.	Conservative Treatment 11/01/2015 - "We studied the clinical characteristics and course of serous cystadenoma in patients undergoing surgery or conservative management only at an academic referral center. " 11/01/2003 - "Conservative treatment is justified only for well documented asymptomatic serous cystadenomas." 09/15/2002 - "Conservative management is wholly justified for serous cystadenoma without complications, whereas mucinous cystadenoma can be cured by pancreatic resection. " 06/01/2003 - "Presence of microcysts within a cystic tumor of the pancreas is usually considered as specific of serous cystadenoma and leads to conservative management and surveillance of asymptomatic patients. " 05/01/2000 - "Some lesions are benign (pseudocyst, serous cystadenoma) requiring conservative management and follow-up, whereas others are premalignant (mucinous cystadenoma, intraductal papillary mucinous tumor.) or frankly malignant (cystadenocarcinoma) and require surgical resection when possible. "
2.	Choledochostomy 01/01/2006 - "We made a preoperative diagnosis of macrocystic serous cystadenoma (SCA) of the pancreas, but did not perform palliative choledochojejunostomy because aspiration of the pancreatic cystic fluid caused the cysts to shrink and relieved the compressive stenosis of the common bile duct (CBD) during the operation. "
3.	Drug Therapy (Chemotherapy) 09/01/1989 - "In the present study, a 22-year-old, nulliparous woman was presented, who had had her right ovary extirpated for serous cystadenoma (low potential for malignancy) and had undergone chemotherapy previously. "
4.	Pancreatectomy 12/01/2021 - "We report the case of a woman who underwent a partial pancreatectomy for a serous cystadenoma when aged 56 years. " 01/01/2021 - "A pancreatic serous cystadenoma was suspected, and a laparoscopic distal pancreatectomy was performed. " 07/01/2020 - "Rong central pancreatectomy for serous cystadenoma in middle segmental pancreas could achieve feasible results." 05/01/2018 - "A solid serous cystadenoma was suspected based on these radiological findings, and middle segment pancreatectomy was performed as a function-preserving surgery. " 05/01/2018 - "Middle segment pancreatectomy for a solid serous cystadenoma diagnosed by MRCP and review of the literature: A case report."
5.	Pancreaticoduodenectomy 04/01/2015 - "We performed subtotal stomach-preserving pancreaticoduodenectomy, and histopathological diagnosis was serous cystadenoma. " 04/01/2000 - "For a symptomatic serous cystadenoma, duodenum-preserving pancreatic head resection is a good alternative to partial duodenopancreatectomy. " 04/01/2023 - "Serous cystadenoma of head pancreas masquerading as pancreatic neuroendocrine tumor: Treated by Whipple's pancreaticoduodenectomy." 01/01/2022 - "748 patients underwent pancreaticoduodenectomy for (n = 541,72.3%) IPMN, (n = 87,11.6%) MCN, (n = 78,10.4%) serous cystadenoma, and (n = 42,5.6%) solid pseudopapillary neoplasm. " 01/01/2003 - "Although serous cystadenoma of the pancreas has essentially a benign nature, pylorus-preserving pancreatoduodenectomy is the treatment of choice when available to avoid the recurrence of obstructive jaundice."